Simvastatin inhibits smoke-induced airway epithelial injury: Implications for COPD therapy

European Respiratory Journal

Volumn 42, Issue 2, 2013, Pages 350-361

  Davis, Benjamin B ^a   Zeki, Amir A ^a   Bratt, Jennifer M ^a   Wang, Lei ^a   Filosto, Simone ^a   Walby, William F ^a   Kenyon, Nicholas J ^a   Goldkorn, Tzipora ^a   Schelegle, Edward S ^a   Pinkerton, Kent E ^a  

^a UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

SIMVASTATIN; TOBACCO SMOKE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIINFLAMMATORY ACTIVITY; ARTICLE; CELL INFILTRATION; CHRONIC OBSTRUCTIVE LUNG DISEASE; CONTROLLED STUDY; DRUG EFFICACY; DRUG MECHANISM; HISTOPATHOLOGY; LEUKOCYTE; LUNG FUNCTION TEST; LUNG PARENCHYMA; MACROPHAGE; NEUTROPHIL; NEUTROPHILIC LUNG INFLAMMATION; NONHUMAN; PNEUMONIA; PRIORITY JOURNAL; PROTECTION; RAT; RESPIRATORY EPITHELIUM; RESPIRATORY TRACT INJURY; TREATMENT DURATION;

ANIMALS; ANTI-INFLAMMATORY AGENTS; BRONCHOALVEOLAR LAVAGE FLUID; CHOLESTEROL; EPITHELIUM; INFLAMMATION; LEUKOCYTES; MACROPHAGES; MALE; MONOMERIC GTP-BINDING PROTEINS; NEUTROPHILS; OXIDATIVE STRESS; PULMONARY DISEASE, CHRONIC OBSTRUCTIVE; RATS; RATS, INBRED SHR; RESPIRATORY FUNCTION TESTS; RHO GTP-BINDING PROTEINS; SIMVASTATIN; SMOKE; TOBACCO; TREATMENT OUTCOME;

EID: 84882598474     PISSN: 09031936     EISSN: 13993003     Source Type: Journal    
DOI: 10.1183/09031936.00042512     Document Type: Article

References (61)

1. Minai OA, Benditt J, Martinez FJ. Natural history of emphysema. Proc Am Thorac Soc 2008; 5: 468-474.
2. Snider GL. Epidemiology and natural history of COPD. In Leff AR, ed. Pulmonary and Critical Care Pharmacology and Therapeutics. New York, McGraw-Hill, 1996; pp. 821-828.
3. Zeki AA, Schivo M, Chan AL, et al. Geoepidemiology of COPD and idiopathic pulmonary fibrosis. J Autoimmun 2010; 34: J327-J338.
4. Jeffery PK. Structural and inflammatory changes in COPD: a comparison with asthma. Thorax 1998; 53: 129-136.
5. Fournier M, Lebargy F, Le Roy LF, et al. Intraepithelial T-lymphocyte subsets in the airways of normal subjects and of patients with chronic bronchitis. Am Rev Respir Dis 1989; 140: 737-742.
6. Saetta M, Turato G, Facchini FM, et al. Inflammatory cells in the bronchial glands of smokers with chronic bronchitis. Am J Respir Crit Care Med 1997; 156: 1633-1639.
7. Grashoff WF, Sont JK, Sterk PJ, et al. Chronic obstructive pulmonary disease: role of bronchiolar mast cells and macrophages. Am J Pathol 1997; 151: 1785-1790.
8. Saetta M, Di Stefano A, Turato G, et al. CD8+ T-lymphocytes in peripheral airways of smokers with chronic obstructive pulmonary disease. Am J Respir Crit Care Med 1998; 157: 822-826.
9. Zeki AA, Kenyon NJ, Goldkorn T. Statin drugs, metabolic pathways, and asthma: a therapeutic opportunity needing further research. Drug Metab Lett 2011; 5: 40-44.
10. Takeda N, Kondo M, Ito S, et al. Role of RhoA inactivation in reduced cell proliferation of human airway smooth muscle by simvastatin. Am J Respir Cell Mol Biol 2006; 35: 722-729.
11. Alexeeff SE, Litonjua AA, Sparrow D, et al. Statin use reduces decline in lung function: VA Normative Aging Study. Am J Respir Crit Care Med 2007; 176: 742-747.
12. Hothersall E, McSharry C, Thomson NC. Potential therapeutic role for statins in respiratory disease. Thorax 2006; 61: 729-734.
13. Lawes CM, Thornley S, Young R, et al. Statin use in COPD patients is associated with a reduction in mortality: a national cohort study. Prim Care Respir J 2012; 21: 35-40.
14. Søyseth V, Brekke PH, Smith P, et al. Statin use is associated with reduced mortality in COPD. Eur Respir J 2007; 29: 279-283.
15. Frost FJ, Petersen H, Tollestrup K, et al. Influenza and COPD mortality protection as pleiotropic, dose-dependent effects of statins. Chest 2007; 131: 1006-1012.
16. Mancini GB, Etminan M, Zhang B, et al. Reduction of morbidity and mortality by statins, angiotensin-converting enzyme inhibitors, and angiotensin receptor blockers in patients with chronic obstructive pulmonary disease. J Am Coll Cardiol 2006; 47: 2554-2560.
17. Keddissi JI, Younis WG, Chbeir EA, et al. The use of statins and lung function in current and former smokers. Chest 2007; 132: 1764-1771.
18. Blamoun AI, Batty GN, DeBari VA, et al. Statins may reduce episodes of exacerbation and the requirement for intubation in patients with COPD: evidence from a retrospective cohort study. Int J Clin Pract 2008; 62: 1373-1378.
19. Maher BM, Dhonnchu TN, Burke JP, et al. Statins alter neutrophil migration by modulating cellular Rho activity-a potential mechanism for statins-mediated pleotropic effects? J Leukoc Biol 2009; 85: 186-193.
20. Sadeghi MM, Collinge M, Pardi R, et al. Simvastatin modulates cytokine-mediated endothelial cell adhesion molecule induction: involvement of an inhibitory G protein. J Immunol 2000; 165: 2712-2718.
21. Jacobson TA. Comparative pharmacokinetic interaction profiles of pravastatin, simvastatin, and atorvastatin when coadministered with cytochrome P450 inhibitors. Am J Cardiol 2004; 94: 1140-1146.
22. Sun XF, Wang LL, Wang JK, et al. Effects of simvastatin on lung injury induced by ischaemia-reperfusion of the hind limbs in rats. J Int Med Res 2007; 35: 523-533.
23. Fessler MB, Young SK, Jeyaseelan S, et al. A role for hydroxy-methylglutaryl coenzyme a reductase in pulmonary inflammation and host defense. Am J Respir Crit Care Med 2005; 171: 606-615.
24. Zeki AA, Franzi L, Last J, et al. Simvastatin inhibits airway hyperreactivity: implications for the mevalonate pathway and beyond. Am J Respir Crit Care Med 2009; 180: 731-740.
25. Liao JK. Isoprenoids as mediators of the biological effects of statins. J Clin Invest 2002; 110: 285-288.
26. Lee JH, Lee DS, Kim EK, et al. Simvastatin inhibits cigarette smoking-induced emphysema and pulmonary hypertension in rat lungs. Am J Respir Crit Care Med 2005; 172: 987-993.
27. Ou XM, Wen FQ, Uhal BD, et al. Simvastatin attenuates experimental small airway remodelling in rats. Respirology 2009; 14: 734-745.
28. Davis BB, Shen Y, Tancredi DJ, et al. Leukocytes are recruited through the bronchial circulation to the lung in a spontaneously hypertensive rat model of COPD. PLoS One 2012; 7: e33304.
29. Davis BB, Liu JY, Tancredi DJ, et al. The anti-inflammatory effects of soluble epoxide hydrolase inhibitors are independent of leukocyte recruitment. Biochem Biophys Res Commun 2011; 410: 494-500.
30. Yu B, Kodavanti UP, Takeuchi M, et al. Acute tobacco smoke-induced airways inflammation in spontaneously hypertensive rats. Inhal Toxicol 2008; 20: 623-633.
31. Zhong CY, Zhou YM, Pinkerton KE. NF-kB inhibition is involved in tobacco smoke-induced apoptosis in the lungs of rats. Toxicol Appl Pharmacol 2008; 230: 150-158.
32. Zhong CY, Zhou YM, Douglas GC, et al. MAPK/AP-1 signal pathway in tobacco smoke-induced cell proliferation and squamous metaplasia in the lungs of rats. Carcinogenesis 2005; 26: 2187-2195.
33. Smith KR, Pinkerton KE, Watanabe T, et al. Attenuation of tobacco smoke-induced lung inflammation by treatment with a soluble epoxide hydrolase inhibitor. Proc Natl Acad Sci USA 2005; 102: 2186-2191.
34. Smith KR, Uyeminami DL, Kodavanti UP, et al. Inhibition of tobacco smoke-induced lung inflammation by a catalytic antioxidant. Free Radic Biol Med 2002; 33: 1106-1114.
35. Teague SV, Pinkerton KE, Goldsmith M, et al. Sidestream cigarette smoke generation and exposure system for environmental tobacco smoke studies. Inhal Toxicol 1994; 6: 79-93.
36. Pillsbury HC Jr. Review of the Federal Trade Commission method for determining cigarette tar and nicotine yield. Smoking and Tobacco Control Monograph No. 7; pp. 9-14. Available from: http://cancercontrol.cancer.gov/brp/ tcrb/monographs/7/m7-2.pdf.
37. Chen YJ, Chen P, Wang HX, et al. Simvastatin attenuates acrolein-induced mucin production in rats: involvement of the Ras/extracellular signal-regulated kinase pathway. Int Immunopharmacol 2010; 10: 685-693.
38. Vickers S, Duncan CA, Chen IW, et al. Metabolic disposition studies on simvastatin, a cholesterol-lowering prodrug. Drug Metab Dispos 1990; 18: 138-145.
39. Bratt JM, Franzi LM, Linderholm AL, et al. Arginase enzymes in isolated airways from normal and nitric oxide synthase 2-knockout mice exposed to ovalbumin. Toxicol Appl Pharmacol 2009; 234: 273-280.
40. Eccles KA, Sowden H, Porter KE, et al. Simvastatin alters human endothelial cell adhesion molecule expression and inhibits leukocyte adhesion under flow. Atherosclerosis 2008; 200: 69-79.
41. Yeh YF, Huang SL. Enhancing effect of dietary cholesterol and inhibitory effect of pravastatin on allergic pulmonary inflammation. J Biomed Sci 2004; 11: 599-606.
42. Mrad MF, Mouawad CA, Al-Hariri M, et al. Statins modulate transcriptional activity of heme-oxygenase-1 promoter in NIH 3T3 cells. J Cell Biochem 2012; 113: 3466-3475.
43. Tu YP, Chuang SJ, Chen SC, et al. Simvastatin induces the expression of hemeoxygenase-1 against ischemiareperfusion injury on the testes in rats. Toxicol Lett 2011; 207: 242-250.
44. Hsieh CH, Sun CK, Lu TH, et al. Simvastatin induces heme oxygenase-1 expression but fails to reduce inflammation in the capsule surrounding a silicone shell implant in rats. J Surg Res 2011; 168: 272-280.
45. Hinkelmann U, Grosser N, Erdmann K, et al. Simvastatin-dependent up-regulation of heme oxygenase-1 via mRNA stabilization in human endothelial cells. Eur J Pharm Sci 2010; 41: 118-124.
46. Min KS, Lee YM, Hong SO, et al. Simvastatin promotes odontoblastic differentiation and expression of angiogenic factors via heme oxygenase-1 in primary cultured human dental pulp cells. J Endod 2010; 36: 447-452.
47. Hsu HH, Ko WJ, Hsu JY, et al. Simvastatin ameliorates established pulmonary hypertension through a heme oxygenase-1 dependent pathway in rats. Respir Res 2009; 10: 32.
48. Mason RP, Walter MF, Jacob RF. Effects of HMG-CoA reductase inhibitors on endothelial function: role of microdomains and oxidative stress. Circulation 2004; 109: II34-II41.
49. Bandoh T, Sato EF, Mitani H, et al. Antioxidative potential of fluvastatin via the inhibition of nicotinamide adenine dinucleotide phosphate (NADPH) oxidase activity. Biol Pharm Bull 2003; 26: 818-822.
50. Altintas ND, Atilla P, Iskit AB, et al. Long-term simvastatin attenuates lung injury and oxidative stress in murine acute lung injury models induced by oleic acid and endotoxin. Respir Care 2011; 56: 1156-1163.
51. Guasti L, Marino F, Cosentino M, et al. Prolonged statin-associated reduction in neutrophil reactive oxygen species and angiotensin II type receptor expression: 1-year follow-up. Eur Heart J 2008; 29: 1118-1126.
52. Greenwood J, Steinman L, Zamvil SS. Statin therapy and autoimmune disease: from protein prenylation to immunomodulation. Nat Rev Immunol 2006; 6: 358-370.
53. Ho PC, Chang KC, Chuang YS, et al. Cholesterol regulation of receptor-interacting protein 140 via microRNA-33 in inflammatory cytokine production. FASEB J 2011; 25: 1758-1766.
54. Murphy DM, Forrest IA, Corris PA, et al. Simvastatin attenuates release of neutrophilic and remodeling factors from primary bronchial epithelial cells derived from stable lung transplant recipients. Am J Physiol Lung Cell Mol Physiol 2008; 294: L592-L599.
55. Wang W, Le W, Ahuja R, et al. Inhibition of inflammatory mediators: role of statins in airway inflammation. Otolaryngol Head Neck Surg 2011; 144: 982-987.
56. Kinsella A, Raza A, Kennedy S, et al. The impact of high-dose statin therapy on transendothelial neutrophil migration and serum cholesterol levels in healthy male volunteers. Eur J Clin Pharmacol 2011; 67: 1103-1108.
57. Dunzendorfer S, Rothbucher D, Schratzberger P, et al. Mevalonate-dependent inhibition of transendothelial migration and chemotaxis of human peripheral blood neutrophils by pravastatin. Circ Res 1997; 81: 963-969.
58. Zhang S, Rahman M, Zhang S, et al. Simvastatin regulates CXC chemokine formation in streptococcal M1 proteininduced neutrophil infiltration in the lung. Am J Physiol Lung Cell Mol Physiol 2011; 300: L930-L939.
59. Parker D, Prince A. Innate immunity in the respiratory epithelium. Am J Respir Cell Mol Biol 2011; 45: 189-201.
60. Schleimer RP, Kato A, Peters A, et al. Epithelium, inflammation, and immunity in the upper airways of humans: studies in chronic rhinosinusitis. Proc Am Thorac Soc 2009; 6: 288-294.
61. Planaguma A, Pfeffer MA, Rubin G, et al. Lovastatin decreases acute mucosal inflammation via 15-epi-lipoxin A4. Mucosal Immunol 2010; 3: 270-279.